Steward Partners Investment Advisory LLC Sells 800 Shares of Esperion Therapeutics Inc (NASDAQ:ESPR)

Share on StockTwits

Steward Partners Investment Advisory LLC trimmed its stake in Esperion Therapeutics Inc (NASDAQ:ESPR) by 22.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,750 shares of the biopharmaceutical company’s stock after selling 800 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Esperion Therapeutics were worth $100,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Marshall Wace LLP purchased a new stake in shares of Esperion Therapeutics in the first quarter worth approximately $186,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Esperion Therapeutics in the second quarter worth approximately $203,000. Virginia Retirement Systems ET AL purchased a new stake in shares of Esperion Therapeutics in the second quarter worth approximately $219,000. Bailard Inc. raised its holdings in shares of Esperion Therapeutics by 28.1% in the second quarter. Bailard Inc. now owns 76,200 shares of the biopharmaceutical company’s stock worth $3,545,000 after buying an additional 16,700 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Esperion Therapeutics in the second quarter worth approximately $1,280,000.

In other news, major shareholder Target N. V. Biotech purchased 80,000 shares of the stock in a transaction on Wednesday, September 4th. The stock was bought at an average price of $33.78 per share, with a total value of $2,702,400.00. Following the transaction, the insider now owns 3,652,964 shares in the company, valued at approximately $123,397,123.92. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Target N. V. Biotech purchased 75,000 shares of the stock in a transaction on Wednesday, November 6th. The shares were purchased at an average cost of $37.30 per share, with a total value of $2,797,500.00. Following the transaction, the insider now owns 3,727,964 shares in the company, valued at approximately $139,053,057.20. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 167,500 shares of company stock valued at $5,943,925. 7.70% of the stock is currently owned by insiders.

ESPR opened at $37.82 on Friday. The stock’s fifty day moving average is $38.49 and its two-hundred day moving average is $42.58. Esperion Therapeutics Inc has a 52 week low of $33.13 and a 52 week high of $58.90. The company has a quick ratio of 5.65, a current ratio of 5.65 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1.11 billion, a P/E ratio of -5.02 and a beta of 1.86.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($2.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.95) by ($0.42). The business had revenue of $0.98 million during the quarter, compared to the consensus estimate of $0.99 million. During the same period in the prior year, the company posted ($1.86) earnings per share. Equities analysts anticipate that Esperion Therapeutics Inc will post -3.02 earnings per share for the current year.

Several brokerages have recently weighed in on ESPR. Northland Securities reiterated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, August 29th. Stifel Nicolaus reduced their price target on Esperion Therapeutics from $112.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, September 17th. BidaskClub upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 29th. Goldman Sachs Group upgraded Esperion Therapeutics from a “sell” rating to a “neutral” rating and reduced their price target for the stock from $55.00 to $45.00 in a report on Monday, September 16th. Finally, Cowen reiterated a “buy” rating on shares of Esperion Therapeutics in a report on Wednesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $70.44.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

See Also: How to Use a Moving Average for TradingĀ 

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.